Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Summarized financial information for the Company’s segments is shown in the following tables:


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenue
Patient services	$	44,627	$	32,967	$	118,793	$	92,375
Dispensary	18,839		17,918		57,736		53,318
Clinical trials & other	1,511		1,390		4,530		5,006
Consolidated revenue	64,977		52,275		181,059		150,699

Direct costs
Patient services	36,126		25,391		96,379		72,051
Dispensary	15,738		15,279		47,816		45,639
Clinical trials & other	113		182		400		494
Total segment direct costs	51,977		40,852		144,595		118,184

Depreciation expense
Patient services	316		181		848		447
Dispensary	—		1		—		1
Clinical trials & other	1		83		4		86
Total segment depreciation expense	317		265		852		534

Amortization of intangible assets
Patient services	688		573		1,995		1,701
Dispensary	—		—		—		—
Clinical trials & other	53		53		158		158
Total segment amortization	741		626		2,153		1,859

Operating income
Patient services	7,497		6,822		19,571		18,176
Dispensary	3,101		2,638		9,920		7,678
Clinical trials & other	1,344		1,072		3,968		4,268
Total segment operating income	11,942		10,532		33,459		30,122

Selling, general and administrative expense	31,963		12,730		90,117		35,120
Non-segment depreciation and amortization	76		(41)		214		28
Total consolidated operating loss	$	(20,097)	$	(2,157)	$	(56,872)	$	(5,026)